ARTL 10-Q: SEC filing

Artelo Biosciences

Filed with the SEC on · accession 0001640334-26-001776

ARTL filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. The quarterly report: unaudited results for the quarter plus management’s comments.

Summary of the filing

Artelo Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing financing activities including equity agreements and an at-the-market offering.

Key details

FilerArtelo Biosciences, Inc.
Placement agentCraft Capital Management LLC
Financing counterpartyLabrys Fund II LP
Financing counterpartyVanquish Funding Group Inc.
Financing counterpartyBoot Capital LLC

✦ Ask GOAX AI about this filing — what it means for ARTL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ARTL?

Click here

Frequently asked questions

What did ARTL file with the SEC on Nov 12, 2026?

ARTL filed a 10-Q (SEC filing). Artelo Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results and disclosing financing activities including equity agreements and an at-the-market offering.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

Other ARTL SEC filings

Get alerts when ARTL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days